The BormioAdvance revolution begins: an alternative to glass tubing containers

The BormioAdvance revolution begins: an alternative to glass tubing containers
BormioAdvance is the name given to an innovative process developed by the Glass Pharmaceuticals Division to create moulded vials with outstandingly even glass distribution and an approximate weight reduction of 30% compared to conventional vials of corresponding type.

The company's long experience in manufacturing lightweight containers for various uses provided the necessary background expertise for developing this new technology.

As an ongoing partner of leading pharmaceutical multinationals, the Glass Pharmaceuticals Division's aim was to bring to the market a reliable and secure solution ready for immediate production. Thanks to BormioAdvance the company is preparing to launch a range of glass vials that combines advantages in cost savings and convenience with vastly improved performance compared to existing products in the field of freeze-drying and sterilisation in general.

ICSE Europe therefore offers an unmissable opportunity to see a preview presentation of the new Delta line ... at stand 4E16.

For further information on the Glass Pharmaceuticals Division's product catalogue - including glass vials, tablet containers, vials - visit our website http://www.bormioliroccoglasspack.com

Bormioli Rocco has developed a sophisticated technology that makes it possible to produce moulded glass vials with optimum glass distribution and an approximate weight reduction of 30% compared to conventional vials of corresponding type.
The launch of the new Delta line of pharmaceutical packaging for injectables will take place at ICSE Europe.

Online PR News - 06-October-2010 - Bormioli Rocco has developed a sophisticated technology that makes it possible to produce moulded glass vials with optimum glass distribution and an approximate weight reduction of 30% compared to conventional vials of corresponding type.
The launch of the new Delta line of pharmaceutical packaging for injectables will take place at ICSE Europe.

Bormioli Rocco has made another technological breakthrough capable of revolutionising the world of pharmaceutical packaging and offering an alternative to glass tubing, in terms of both economic convenience and industrial performance.

Suggested Articles

The agency has granted Tecentriq a priority review in previously untreated NSCLC, setting up the Roche drug for an approval decision by June 19.

Warren Buffett's Berkshire Hathaway has built a $192 million stake in Biogen, a risky investment considering aducanumab's uncertain future.

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.